Sarcomas consists of a mixture of rare solid tumors, accounting for approximately 1% of all adult cancers. In general, they are categorized into two groups namely soft tissue sarcoma (STS) (includes fat, muscle, nerve and nerve sheath, blood vessels and other connective tissue) and sarcomas of bone. Undifferentiated pleomorphic, GIST, liposarcoma and leiomyosarcoma are among the most common subtypes of STS. Surgery is standard of care as primary treatment for most STS patients, with chemotherapy and/or radiation used prior to surgery. Current development for STS spans multiple mechanisms of action and targets.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in soft tissue sarcoma to help guide strategic and tactical commercial development decisions for market participants.